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Protein kinase A (PKA), the main effector of cAMP in eukaryotes, is a paradigm for the
mechanisms of ligand-dependent and allosteric regulation in signalling. Here we report the
orthologous but cAMP-independent PKA of the protozoan Trypanosoma and identify 7-deaza-
nucleosides as potent activators (EC50≥ 6.5 nM) and high afﬁnity ligands (KD≥ 8 nM). A co-
crystal structure of trypanosome PKA with 7-cyano-7-deazainosine and molecular docking
show how substitution of key amino acids in both CNB domains of the regulatory subunit and
its unique C-terminal αD helix account for this ligand swap between trypanosome PKA and
canonical cAMP-dependent PKAs. We propose nucleoside-related endogenous activators of
Trypanosoma brucei PKA (TbPKA). The existence of eukaryotic CNB domains not associated
with binding of cyclic nucleotides suggests that orphan CNB domains in other eukaryotes
may bind undiscovered signalling molecules. Phosphoproteome analysis validates 7-cyano-7-
deazainosine as powerful cell-permeable inducer to explore cAMP-independent PKA sig-
nalling in medically important neglected pathogens.
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The mechanisms of protein kinase regulation, speciﬁcally bysmall second messenger molecules, have been studied ingreat detail using protein kinase A (PKA) as a paradigm1.
PKA, discovered 50 years ago, is present in most eukaryotes
except plants, has a highly conserved structure, and is the main
effector of the second messenger cAMP. Hence, the synonym
cAMP-dependent protein kinase is commonly used. The inactive
PKA holoenzyme is a complex of regulatory (PKAR) and catalytic
(PKAC) subunits, either as R-C heterodimer or R2-2C hetero-
tetramer. The R2 homodimer is formed by an N-terminal
dimerization/docking (DD) domain that also mediates sub-
cellular localization via A kinase anchoring proteins (AKAPs).
Two C-terminal cyclic nucleotide binding (CNB) domains
cooperatively bind two molecules of cAMP, resulting in a con-
formational change of the R subunit that releases the active cat-
alytic kinase subunit(s) from the inhibitory pseudo-substrate or
substrate site of PKAR. The CNB domain is an ancient evolu-
tionarily conserved domain family with >7500 members that
confers ligand-dependent allosteric regulation to a diverse range
of proteins2. In eukaryotes, CNB domains are bound and regu-
lated by cyclic nucleotides. In bacterial transcription factors, some
CNB domains can bind other ligands like heme in the case of the
CO sensing transcription activator CooA3 or chlorinated phenolic
compounds in CprK, a member of the ubiquitous CRP-FNR
family of transcription activators4. In metazoans, PKA has diverse
functions ranging from metabolism and gene regulation to
development, motility, and memory5. Many of these functions are
tissue-speciﬁc and compartmentalized at the subcellular level6. In
lower eukaryotes including fungi or apicomplexan protozoa like
Plasmodium and Toxoplasma, PKA plays key roles in nutrient
sensing, developmental switches, or infectivity processes7–9. Most
species encode one or two PKAR isoforms and several PKAC
isoforms10. The resulting holoenzyme isoforms differ in cell type-
speciﬁcity, developmental expression, sub-cellular localization,
and afﬁnity to cAMP, thereby accounting for the pleiotropic
functions of cAMP signalling.
Trypanosoma brucei species are kinetoplastid parasites that
infect a large variety of mammals, causing severe disease in
domestic animals with important economic losses in endemic
countries. The parasite is also causative of the deadly human
African sleeping sickness, a neglected tropical disease11. Trans-
mission is restricted to the habitat of the Tsetse ﬂy in tropical
Africa. Development of the parasite in the host and vector is a
prerequisite for transmission. This developmental process can be
induced by cAMP analogues12–14, although this is mediated by
intracellular hydrolysis products of these analogues15 operating
via a complex network of effectors16. The parasite has been
shown to release cAMP as a mechanism of evading the host’s
innate immunity17. Essential roles of intracellular cAMP signal-
ling have also been documented for cell division12,18–20 and social
motility21. It is therefore surprising that all attempts to detect
cAMP-dependent kinase activity in African trypanosomes have
failed22–27. Genes encoding three PKA catalytic subunit ortho-
logues and one regulatory subunit orthologue have been identi-
ﬁed in the T. brucei genome22,26,28, whereas alternative cAMP
effectors like EPAC orthologues and cNMP-gated ion channels
were not detected. By screening a genome-wide RNAi library for
cAMP resistance in T. brucei, we identiﬁed a novel cAMP binding
protein (CARP1) unique to kinetoplastids29, yet PKA was not
among the hits of the screen. The catalytic subunits of T. brucei
PKA are highly conserved with the presence of all 11 canonical
kinase subdomains, the essential threonine in the kinase activa-
tion loop, and conserved residues implicated in mammalian
PKAC’s binding to the regulatory PKAR subunits30. TbPKAR has
a conserved C-terminal part with two CNB domains and the PKA
substrate motif (RRTTV) that interacts with and inhibits PKAC.
TbPKAR differs from its metazoan orthologues by an extended
N-terminal domain with leucine-rich repeats (LRR) (Fig. 1a).
Some amino acid substitutions of consensus residues in the
cAMP binding pockets have been noticed in sequence
alignments22,31. The link between cAMP and PKA remains elu-
sive in Trypanosoma in spite of the excellent overall conservation
of the kinase.
There is a surprising deﬁcit of knowledge in signalling
mechanisms in these phylogenetically distant organisms and no
complete pathway from receptor to effector has been elucidated
to date. A possible explanation for this knowledge gap is sug-
gested by the domain architectures found in the kinome of try-
panosomes: few known signalling domains or protein–protein
interaction domains are linked to the catalytic kinase domains of
the 176 identiﬁed protein kinases. In addition, unusual domain
combinations prevail32. Many conserved signalling effectors are
likely to be differently connected and wired in various pathway
architectures in these phylogenetically distant protozoa. This
might also be the case for some second messenger dependencies.
Here, we show that Trypanosoma PKA is not a cyclic nucleotide-
dependent protein kinase. We use a chemical biology approach to
identify highly speciﬁc activators of Trypanosoma PKA. The
ﬁrst crystal structure of a kinetoplastid PKAR explains the
structural requirements for ligand selectivity. We suggest that this
PKA has evolved to bind novel ligand(s), possibly taking the role
of second messenger(s) in T. brucei. Our new activators are
excellent tools to study this cAMP-independent PKA signalling in
trypanosomes.
Results
PKA holoenzymes in Trypanosoma brucei. We ﬁrst established
that the orthologous PKA subunit genes in T. brucei do encode
proteins able to form the expected holoenzyme complexes of
regulatory (R) and catalytic (C) subunits. One allele of PKAC1
was Ty1-epitope tagged in situ, while the second PKAC1 allele
was deleted to generate T. brucei cell line Δc1/Ty1-C1 (Fig. 1b).
The absence of a wild type PKAC1 allele allowed simultaneous
detection of the highly similar PKAC2 isoform by a PKAC1/2-
speciﬁc antibody (Fig. 1c and Supplementary Fig. 1a). PKAR was
then C-terminally PTP-tagged in situ in cell line Δc1/Ty1-C1 to
generate Δc1/Ty1-C1 R-PTP (Fig. 1b, c). All three PKA catalytic
subunit isoforms were pulled down by PKAR-PTP from lysates of
cell line Δc1/Ty1-C1 R-PTP but not from the control cell line Δc1/
Ty1-C1 (Fig. 1d). Pull down from cell lines expressing Ty1- or
HA-tagged PKAC or PKAR subunits independently conﬁrmed
the interactions between PKAR and each of PKAC1, 2, 3 in a
heterodimeric complex (Supplementary Fig. 1b, c). No co-
precipitation of untagged PKAR or other PKAC isoforms was
observed with tagged PKAR or PKAC1, 2, or 3 (Fig. 1d and
Supplementary Fig. 1c), indicating the absence of a tetrameric R2-
2C complex that is found in mammalian PKA. Heterodimeric
PKAR-C complexes are not unusual in lower eukaryotes27,33,34.
The catalytic function of the kinase is essential for growth and
viability, as RNAi-mediated repression of the catalytic subunits
PKAC1/2 or PKAC3 is lethal or growth inhibitory, respectively35
(Supplementary Fig. 2). Severe cell division defects are detected,
as cytokinesis stages and multinucleated cells accumulate. This
phenotype is frequently found when targeting essential trypano-
some genes36. It does not necessarily indicate a speciﬁc role in
cytokinesis. RNAi-mediated repression of PKAR has a very
similar phenotype due to the rapid decrease of free PKAC1
(Supplementary Fig. 2). This indicates degradation of free PKAC
released upon holoenzyme dissociation, as was observed for
PKAC in mammalian cells37. Nevertheless, cell clones can be
selected that maintain a basal PKAC1 level sufﬁcient for survival
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09338-z
2 NATURE COMMUNICATIONS |         (2019) 10:1421 | https://doi.org/10.1038/s41467-019-09338-z | www.nature.com/naturecommunications
after homozygous deletion of PKAR. The resulting Δpkar/Δpkar
cell lines38 used later in this work show a mild growth phenotype
with population doubling time (PDT) of 7.5 h versus 5.4 h for
wild type cells.
Trypanosoma PKA is not activated by cAMP. The PKA
holoenzymes were immunoprecipitated from trypanosomes
expressing epitope-tagged PKA subunits to assay PKA activity.
Contaminating kinase activities in the precipitate were excluded
as (1) Ty1-afﬁnity puriﬁcation from wild type cells or cells
expressing a catalytically inactive Ty1-PKAC1 N153A mutant39
did not pull down PKA-speciﬁc activity and (2) phosphorylation
of the PKA-speciﬁc substrate kemptide was inhibited by the PKA-
speciﬁc pseudo-substrate peptide PKI(5–24)40 (Supplementary
Fig. 3a). The basal activity of holoenzymes immunoprecipitated
from cells expressing PKAR-Ty1 or Ty1-PKAC1 or HA-PKAC2
was not increased by cAMP (Supplementary Fig. 3b), even when
the cyclic nucleotide was added at unphysiologically high con-
centrations (1 mM). In the same experiments, cGMP activated at
≥100 µM (Supplementary Fig. 3b). Some activation by cGMP had





























































































Fig. 1 PKA holoenzyme complexes in T. brucei. a Domain architecture of PKAR (top) and PKAC (bottom) orthologues from T. brucei (Tb) (TriTrypDB
accessions: PKAR, Tb927.11.4610; PKAC1, Tb927.9.11100; PKAC2, Tb927.9.11030; PKAC3, Tb927.10.13010) compared to human (Hs) PKA (Uniprot
accessions: PKARIα, P10644; PKACα, P17612). LRR leucine-rich repeat region, DD dimerization/docking domain, CNB cyclic nucleotide binding domain,
kinase kinase domain. b Genotypes of cell lines with in situ tagged PKAC1 (Ty1-C1, cyan; Ty1 epitope tag in magenta) and PKAR (R-PTP, blue; PTP-tag in
black) compared to wild type (WT). The phleomycin resistance cassette (BLE, grey) is indicated. c Two-colour ﬂuorescent western blot analysis of the
double tagged cell line (Δc1/Ty1-C1 R-PTP) using anti-PKAR and anti-PKAC1/2 (left panel, red signals), and anti-Ty1 and anti-PFR-A/C (loading control)
(middle panel, green signals). The merge of both channels is shown on the right panel. Ty1 causes a mobility shift of PKAC1 and enables the detection of
PKAC2 in cell lines devoid of wild type PKAC1. Note that PKAC1 and PKAR appear as doublet bands that we interpret as modiﬁcation (PKAC1*) and allelic
polymorphism, respectively, in the MiTat 1.2 cell line. d PTP afﬁnity puriﬁcation followed by western blot analysis of double tagged and control cell lines
using antibodies as in c and anti-PKAC3. Equivalent amounts of soluble input material (IN), ﬂow-through (FT), washes, and 13 equivalents of the eluate
(Elu) were loaded. Source data to c and d are provided as a Source Data ﬁle
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the presence of cGMP or cGMP signalling in trypanosomatids41,
minimizing the likelihood that cGMP is a physiological activator
of the kinase. The unconventional cyclic nucleotides cXMP,
cIMP, cCMP, and cUMP also did not show any signiﬁcant effects
(Supplementary Fig. 3c). In order to exclude unsuitable assay
conditions, an in vivo assay for PKA activity was established that
is based on transgenic expression of the heterologous PKA sub-
strate VASP (human platelet vasodilator stimulated phospho-
protein) in T. brucei. Phosphorylation of VASP at the PKA site
Ser-157 causes an electrophoretic mobility shift from 46 to 50
kDa42 (Supplementary Fig. 3e). Non-phosphorylated (46 kDa)
and phosphorylated VASP (50 kDa) were quantiﬁed by western
blot analysis. The ratiometric determination of VASP phos-
phorylation (non-phosphorylated/phosphorylated) is a reliable
proxy for PKA activity. The myristoylated membrane-permeable
peptide inhibitor myr-PKI(14–22)40 reduced the measured
activity to background (Supplementary Fig. 3f). We then exam-
ined the effects of cAMP on PKA activity in live cells by three
independent approaches. First, pharmacological elevation of
intracellular cAMP was accomplished by inhibition of phospho-
diesterases (PDEs) with a highly potent inhibitor of trypanosomal
PDEs (CpdA, now renamed as NPD-001). The intracellular
cAMP content increased up to 600-fold upon treatment with
CpdA (Fig. 2a) but did not elicit any change in in vivo PKA
activity (Fig. 2b). Second, reverse genetic elevation of intracellular
cAMP was achieved by inducible RNAi-mediated depletion of the
major cAMP-speciﬁc PDEs, PDEB1 and PDEB220. The resulting
45-fold increase of cAMP content (Fig. 2c) also did not stimulate
PKA activity (Fig. 2d). Third, VASP expressing cells were treated
with membrane-permeable cAMP analogues 8-pCPT-cAMP, 8-
pCPT-2′-O-Me-cAMP, or cAMP-AM (see Supplementary
Table 1). The latter is a prodrug cleaved by esterases to deliver
cAMP intracellularly43. No PKA activation was detected for any
of the analogues up to 1 mM (Supplementary Fig. 3h).
Membrane-permeable cGMP derivatives also had no effect on
PKA activity in vivo (Supplementary Fig. 3i).
The drug dipyridamole induces PKA activity in trypanosomes.
The most compelling evidence against cAMP-dependent PKA
activity in trypanosomes is the lack of any change in kinase
activity upon an up to 600-fold increase in intracellular cAMP
content, caused by the PDE inhibitor CpdA. Prior to the avail-
ability of CpdA, the same experiment was done with dipyr-
idamole, a potent inhibitor of mammalian PDEs44 with modest
activity against trypanosomal PDEs15,45. Initially, we were misled
by a dose- and time-dependent induction of VASP phosphoryla-
tion by dipyridamole (Fig. 2e, f, Table 1) that correlated with a
moderate increase in intracellular cAMP content (Fig. 2g). As the
data shown in Fig. 2a–d provide strong evidence that this effect by
dipyridamole cannot be caused by the increase in cAMP, dipyr-
idamole must induce PKA activity either directly or indirectly by a
cAMP-independent mechanism. Yet, the effect is clearly mediated
by PKAR, as no induction was detected in a VASP reporter cell
line with homozygous deletion of PKAR (Fig. 2h).
Compound screening for activators of TbPKA. Dipyridamole, a
licensed drug inhibiting thrombocyte aggregation, is a PDE
inhibitor but also interferes with adenosine transport and meta-
bolism46. The possible link between PKA activation and purine
metabolism motivated a targeted compound screen. We tested 13
different purine nucleoside or nucleotide analogues (Supple-
mentary Table 1) for activity in the in vivo PKA reporter assay.
Most of them are predicted to be membrane permeable due to
lipophilic groups. Out of these, the four 7-deazaadenosine
(tubercidin, Tu) analogues toyocamycin (Toyo), 5-iodo-
tubercidin (5-I-Tu), 5-bromo-tubercidin (5-Br-Tu), and sangi-
vamycin induced PKA activity with EC50 values of 88 nM, 390
nM, 625 nM, and 39 µM, respectively (Fig. 3a, Table 1). The
remaining compounds had either a slight inhibitory (8-pCPT-
Ado, 8-pCPT-2-′O-Me-Ado) or no effect (Tu, 8-pCPT-Guo, 2-
Cl-Ado, 8-pCPT-Ade, 6-Br-Tu, 8-Br-Ado, 6-Cl-PuR) in the PKA
reporter assay (Fig. 3, Supplementary Fig. 4a). The most potent
activator, toyocamycin, did not induce phosphorylation of VASP
in the pkar knock out genetic background (Supplementary
Fig. 4b), demonstrating that PKA is the target kinase. Growth or
viability of the parasites was affected by continuous treatment
with all 7-deazaadenosine analogues (Table 1). However, this was
apparently due to off-target effects, as the drugs had very similar
effects on pkar knock out cells (Table 1). Since these analogues
are known to target multiple proteins and processes in mam-
malian cells, including kinases and synthesis of DNA, RNA, and
proteins (reviewed in ref. 47), growth or viability phenotypes were
expected.
7-Deazaadenosine analogues bind and activate TbPKAR. The
identiﬁed compounds may activate trypanosome PKA either
directly or indirectly in the cell-based reporter assay. To address
this, tagged PKAR and PKAC1 subunits were co-expressed in
the heterologous Leishmania tarentolae expression system and
the holoenzyme complex was isolated by tandem afﬁnity pur-
iﬁcation (Supplementary Fig. 4e, inset). In vitro kinase assays
with kemptide and [32P]-ATP as substrates showed kinase
activation upon addition of tubercidin and 5-substituted
tubercidin analogues with the following order of potency: 5-I-
Tu > Toyo > 5-Br-Tu > tubercidin > sangivamycin (Fig. 3a,
Table 1). The EC50 values measured with recombinant T. brucei
holoenzyme puriﬁed from L. tarentolae were in the same order
of magnitude as the EC50 values of the in vivo PKA reporter
assay. Up to 3.4-fold differences between in vitro kinase assay
and cell-based assay are likely due to uptake, accumulation, or
metabolism of the individual compounds in trypanosome cells.
Tubercidin enters the trypanosome cell via nucleoside trans-
porters48, while the 5-substituted analogues are more lipophilic
and predicted to cross the cell membrane by passive diffusion.
Tubercidin uptake might be too slow to cause PKA activation
within the time frame of the in vivo reporter assay. The evi-
dence for a direct mode of action provided by in vitro kinase
assays was further corroborated by measuring binding para-
meters between the activating compounds and puriﬁed N-
terminally truncated T. brucei PKAR(199–499) expressed in
Escherichia coli (Supplementary Fig. 4h). Isothermal titration
calorimetry (ITC) determined a KD of 57 nM for toyocamycin
with a ligand to protein molar ratio of 2.1 (±0.2), indicating
availability of both CNB sites for binding (Fig. 3a, Table 1). A
slightly lower KD of 32 nM was obtained for 5-I-Tu with a
ligand to protein molar ratio of only 1.2 (±0.2). We suggest that
5-I-Tu has a preference for one binding site, whereas the KD
value for Toyo averages over both binding sites. This is sup-
ported by the different thermodynamic signatures that indicate
enthalpically-driven binding, which for 5-I-Tu is counteracted
by a negative entropic effect (Fig. 3c). It should be noted that all
binding assays are performed with the ligand-free (apo) form of
the PKAR subunit, whereas kinase assays probe the R-C
holoenzyme. Nevertheless, the binding KD values for the ana-
logues are close to the respective EC50 for kinase activation
in vitro. Most importantly, the values for Toyo and 5-I-Tu are
similar to the KD for cAMP binding to mammalian PKARIα
measured under identical conditions (28 ± 5 nM, Supplemen-
tary Fig. 4f and ref. 49). Dipyridamole, whose activation of T.
brucei PKA had initially guided our compound screen, did not
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have any effect in the in vitro kinase assay (Supplementary
Fig. 4e), supporting an indirect mode of action in vivo.
Development of a trypanosome-speciﬁc PKA activator. In
mammalian cells, some nucleoside analogues have been reported
to be signiﬁcantly less toxic when the adenosine moiety is
replaced by inosine50,51. Therefore, as the ﬁrst step in optimiza-
tion, we changed the purine ring side groups of toyocamycin (7-
cyano-7-deazaadenosine) to match inosine, resulting in the
compound 7-cyano-7-deazainosine (7-CN-7-C-Ino). Compared
to Toyo, 7-CN-7-C-Ino had 36-fold higher activation potency on
the puriﬁed holoenzyme (EC50 6.5 ± 4.6 nM) and 7-fold higher
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(Fig. 3b, Table 1). The increased afﬁnity was mainly due to gain in
the entropic component of binding (−TΔS=−2.3 kcal mol−1
versus −0.9 kcal mol−1 for Toyo) (Fig. 3c). This surprising
increase in activation potency upon introduction of a single
structural modiﬁcation did not, however, translate into increased
potency in the in vivo kinase reporter assay (EC50 838 ± 139 nM),
probably due to slower uptake or faster intracellular metabolism
of the 7-deazainosine analogue. In a cell line with homozygous
deletion of PKAC3 and simultaneous RNAi depletion of PKAC1/2
(Supplementary Fig. 4d), phosphorylation of the PKA reporter
substrate VASP was undetectable with or without treatment by 7-
CN-7-C-Ino (Supplementary Fig. 4c). This control fully corro-
borated the PKA speciﬁcity of the in vivo reporter assay based on
VASP Ser-157 phosphorylation in trypanosomes. The cytotoxi-
city of 7-CN-7-C-Ino was drastically reduced compared to Toyo
(>170-fold increase of EC50 for cell viability, Table 1).
7-CN-7-C-Ino, Toyo, or 5-I-Tu did not bind to puriﬁed human
PKARIα, whereas cAMP binding to the same PKARIα prepara-
tions (KD 28 nM, Supplementary Fig. 4f) was intermediate
between the afﬁnities of CNB-A and CNB-B that have been
measured before separately52. Consistently, Toyo did not activate
the mammalian PKARIα2–2PKACα holoenzyme, even at con-
centrations 270-fold above the EC50 for the T. brucei PKA
holoenzyme (Supplementary Fig. 4g). As expected from the kinase
assays (see Fig. 2b, d and Supplementary Fig. 3b), recombinant T.
brucei PKAR did not bind cAMP (Supplementary Fig. 4h). In
summary, a potent, highly speciﬁc, and nontoxic activator of the
cAMP-independent trypanosomal PKA has been developed.
Crystal structure of parasite PKAR with 7-CN-7-C-Ino. To
explore the molecular basis of binding and activation selectivity of
Trypanosoma PKA for 7-deaza nucleoside analogues, we co-
crystallized PKAR with 7-CN-7-C-Ino. The highest resolution X-
ray diffraction data were obtained using truncated PKAR
(200–503) of the related parasite Trypanosoma cruzi (Supple-
mentary Fig. 5, see Supplementary Table 2 for data collection and
reﬁnement statistics) that is highly homologous in primary
sequence (79% identity) and structural alignment to the T. brucei
PKAR fragment. The protein adopts a dumbbell-like structure
(Fig. 4a) consisting of two 8-stranded beta barrels (CNB-A and
CNB-B) linked by an alpha helical element (R337 to N361, three
helices). A 7-CN-7-C-Ino molecule can be clearly recognized on
top of each beta barrel by the electron density in the Fo–Fc omit
map (Fig. 4b, c). In bovine PKAR (PDB 1RGS), the CNB-A and
CNB-B domains are linked via allosteric communication30. When
a cAMP molecule enters the CNB-B of PKAR, it is capped by a
hydrophobic residue (Y371) via π-stacking interaction. This event
triggers the rupture of a salt bridge (E261–R366) and conse-
quently destabilizes the holoenzyme conformation. Tryptophan
W260 thereby moves 30 Å closer to CNB-A where it caps the
second cAMP molecule in that binding site by an analogous π-
stacking interaction. The conformational change releases an
active C-subunit. The amino acids taking part in these sequential
ligand binding events linked to holoenzyme activation are readily
identiﬁed in 7-CN-7-C-Ino-bound T. cruzi PKAR by alignment
with cAMP-bound bovine PKARIα (Fig. 4a, Supplementary
Movie 1). In TcPKAR(200–503) the capping residues in CNB-A
and -B are Y371 and Y483, respectively, while a salt bridge might
be formed by the pair R476–E372. Despite only 35% sequence
identity, the Cα alignment of both structures shows very high
conservation (RMSD, root mean square deviation= 3.25 Å)
including the fragmented αB/C helix (Supplementary Fig. 6,
Supplementary Movie 2) that is key of the conformation change
mediating allosteric activation of bovine PKARIα30.
Both CNB-A and -B pockets are occupied by 7-CN-7-C-Ino
with the ribose moiety in a position very similar to the position of
the ribose moiety of cAMP bound to bovine PKARIα (Fig. 4a,
Table 1 Summary of TbPKA activators
Compound EC50 in vivo PKA
assaya
EC50 in vitro PKA
assayb








7-CN-7-C-Ino 838 ± 139 nM 6.5 ± 4.6 nM 8 ± 2 nM 2 ± 0.2 ≥125 µM ≥125 µM
Toyo 87.6 ± 9.6 nM 234 ± 92 nM 57 ± 25 nM 2.1 ± 0.1 739 ± 59 nM 690 ± 58 nM
5-I-Tu 390 ± 20 nM 203 ± 79 nM 32 ± 9 nM 1.2 ± 0.2 330 ± 38 nM 346 ± 41 nM
5-Br-Tu 625 ± 66 nM 1.7 ± 1.4 µM n.d. n.d. 874 ± 122 nM 1009 ± 95 nM
Tubercidin No effect 5.0 ± 0.5 µM n.d. n.d. n.d. n.d.
Sangivamycin 39.3 ± 5.6 µM 10.8 µM n.d. n.d. 713 ± 40 nM 1548 ± 171 nM
Dipyridamole 22.4 ± 4.2 µM No effect n.d. n.d. 9.9 ± 1 µM 16.3 ± 1.8 µM
aMean ± SD determined from three independent replicates
bMean ± SD of independent replicates; n= 5 (Toyo), n= 4 (7-CN-7-C-Ino; 5-I-Tu), n= 2 (5-Br-Tu), n= 2 (tubercidin), n= 1 (sangivamycin), technical duplicates or triplicates each
cMean ± SD of n= 3 independent replicates
dMean ± SEM determined from independent replicates (Alamar blue cell viability assay): n= 11 (dipyridamole), n= 8 (5-I-Tu; 5-Br-Tu; sangivamycin in pkar KO), n= 7 (Toyo; sangivamycin in WT), n= 6
(7-CN-7-C-Ino)
Fig. 2 T. brucei PKA is not activated by cAMP. a Intracellular [cAMP] (mean ± SD of independent replicates; n= 5 (0min, Mock); n= 6 (DMSO, CpdA))
and b in vivo PKA activity (with western blot inset) in cells treated or not (Mock) for 15 min with the PDE inhibitor CpdA19 (10 µM; now renamed as NPD-
00174) or solvent (1% DMSO). Release of cAMP into the medium upon treatment was neglectable (Supplementary Fig. 3d). c Intracellular [cAMP]
(mean ± SD of n= 3 independent replicates) and d in vivo PKA activity (with western inset) upon inducible (1 µg ml−1 tetracycline) RNAi repression of
PDEB1 and PDEB2. Kinase activity cannot be determined at time 0, since the RNAi cell line (VASPi PDEB1/2 RNAi) and the control line (VASPi) both harbour
a tetracycline inducible VASP transgene. e Dose response of in vivo PKA activity upon 15min treatment with dipyridamole (Dip). f Time course of in vivo
PKA activity upon treatment with 100 µM dipyridamole (Dip) or dipyridamole+myr-PKI(14–22) or solvent (1% DMSO) or Mock. g Intracellular [cAMP]
(mean ± SD of independent replicates; n= 5 (0min, Mock 15 min); n= 3 (Mock 90min); n= 6 (DMSO, Dip)) upon treatment with 100 μM dipyridamole
(Dip) or 1% solvent (DMSO) or Mock for 15 or 90min. h In vivo PKA activity upon treatment as in g for 15 min in wild type (WT), homozygous pkar knock
out and PKAR add-back (in situ rescue) cells. For all in vivo kinase reporter assays, one representative western blot is shown as inset and data points are
mean ± SD of n= 3 independent replicates. Source data are provided as a Source Data ﬁle
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Supplementary Movie 1). The ribose moiety docks to the CNB-A
site by donating two hydrogen bonds (hydroxyl groups O3 and
O5) to E312 (Fig. 4d, Supplementary Movie 3). E310 contacts the
O2 hydroxyl group and at the same time brings Y371 in close
proximity to make a π-stacking interaction with the hypox-
anthine moiety of the ligand. The free electron pair in the cyano
moiety receives a hydrogen bond from the side chain of K294,
while Y300 additionally shields the ligand from the solvent. In the
CNB-B site (Fig. 4e, Supplementary Movie 4), E436 interacts with
the 3′ and 5′ hydroxyl groups of the ribose ring. Y483 acts as a
hydrophobic cap that seems to be positioned via a water-
mediated (w07) hydrogen bonding network formed by the main
chain carbonyl group of H431, the side chain of E434 and the O2
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the purine ring accepts a hydrogen bond from the main chain
nitrogen atom of Y486, while the secondary amine in position 1
acts as a donor to the carbonyl of K482 (Fig. 4e, Supplementary
Movie 4). In the CNB-B site, the cyano group does not engage in
hydrophilic interactions but instead is sandwiched between the
side chains of Y485 and Y486. A sequence alignment of
kinetoplastid and mammalian PKAR (Fig. 4f, g) shows that
alanine residues in both pockets (A202 and A326) of bovine
PKAR are substituted by glutamates in the kinetoplastid PKAR
orthologues. The positively charged arginine residues responsible
for neutralizing the cyclic phosphate of cAMP (R209 and R333 in
bovine PKAR) are substituted in kinetoplastid PKAs by neutral
amino acids with shorter side chains (V, T, A, or N). Thus, few
substitutions in a highly conserved signalling protein are
hallmarks of a ligand selectivity switch from cAMP to 7-CN-7-
C-Ino.
Molecular docking of 7-deaza nucleosides. For the series of 7-
deaza nucleoside analogues, we found a good correlation between
computational docking to the TcPKAR structure and the potency
of activation of the puriﬁed kinase (Supplementary Fig. 7 and
Table 1). Re-docking of the co-crystallized compound 7-CN-7-C-
Ino to the CNB-A and -B sites of TcPKAR gave RMSD values of
0.266 and 0.252, respectively, for the best poses. Using the Glide
E-model (GE) scoring system, the best docking poses of the
compounds were ranked for the A site (7-CN-7-C-Ino > Toyo >
5-Br-Tu > 5-I-Tu > sangivamycin > Tu) and for the B site (7-CN-
7-C-Ino > Tu > Toyo > 5-Br-Tu > 5-I-Tu > sangivamycin). Inter-
estingly, Tu docks very well in the B site but is a weak activator
(see Discussion). The cyano-, iodo-, or bromo- groups at position
5 of all other tubercidin analogues are accommodated in a
hydrophobic pocket formed by the side chains of V444, V489,
Y485, and Y486, the latter three being part of the αD helix
(Supplementary Fig. 7c). 7-CN-7-C-Ino forms two additional
hydrogen bonds (K482/O and Y486/N) with the αD helix com-
pared to Toyo, correlated with a 7-fold higher afﬁnity and 36-fold
higher activation potency (Table 1).
PKA signalling and targets in trypanosomes. PKA downstream
signalling components and targets are so far completely unex-
plored in trypanosomes. To probe PKA target phosphorylation
events, we ﬁrst used a phospho-speciﬁc PKA substrate antibody
detecting the phosphorylated consensus PKA sites RXXS*/T*. A
3–4-fold increase in global RXXS*/T* site phosphorylation was
observed by western blotting after 10 min of Toyo or 7-CN-7-C-
Ino treatment in wild type but not in Δpkar/Δpkar cells (Fig. 5a).
Phosphoproteome analysis under these conditions (15 min ± 7-
CN-7-C-Ino) showed 642 signiﬁcantly (FDR ≤ 0.05, s0= 2)
upregulated phosphosites, mostly containing PKA motifs (77%)
(K/R-X-X-S/T, K/R-X-S/T)5, whereas these PKA motifs were
underrepresented (19%) in the 84 downregulated phosphosites
(Fig. 5b, c; Supplementary Data 1). The frequency distribution of
PKA motif subsets in the 7-CN-7-C-Ino-induced T. brucei
phosphoproteome matches closely with that observed for human
PKA motifs (Fig. 5c). An unbiased motif discovery algorithm
conﬁrmed enrichment of the same PKA motifs among the
upregulated phosphosites (Supplementary Fig. 8a, b). Gene
ontology (GO) enrichment analysis predicts functions of PKA in
posttranscriptional regulation of gene expression, dynamics of
cytoskeletal and organellar structures, signalling, and cell division
and cytokinesis (Supplementary Fig. 8c).
We also explored changes in cellular protein abundance
following PKA activation at later time points (6 and 12 h) by
label-free quantitative proteomics. No signiﬁcantly regulated
proteins were detected 6 h post induction and only 14 proteins
12 h post induction in wild type cells (≥1.5-fold difference at p ≤
0.05, Supplementary Fig. 9), including PKAC1/2 and metacaspase
4 (MCA4)53. The Δpkar/Δpkar mutant trypanosomes served as
negative control. As expected, PKAC1/2 levels decreased rapidly,
resulting from ligand-induced dissociation of the holoenzyme
complex and instability of the free C subunit, as reported for
mammalian PKA37. MCA4, for which an antibody was available,
informed on differential effects of 7-CN-7-C-Ino and Toyo:
whereas both inducers decreased MCA4 abundance in wild type
but not in Δpkar/Δpkar cells 12 h post induction, only Toyo
elevated MCA4 at later time points in a PKA-independent
fashion (Fig. 5d). This is compatible with observed PKA-
independent effects of Toyo on growth (Table 1) due to multiple
cellular targets. 7-CN-7-C-Ino, on the other hand, does not
produce these PKA-independent effects on growth, viability, or
visible phenotype. This compound is therefore proposed as novel
and speciﬁc tool to study in vivo the essential processes regulated
by PKA in trypanosomes.
Discussion
Functionally and biochemically uncharacterized PKAs are reg-
ularly annotated as cyclic AMP-dependent protein kinases due to
high conservation in the eukaryotic kingdom. Here, we have
identiﬁed novel potent activators of cAMP-independent trypa-
nosome PKA and unambiguously show that ligand selectivity has
evolved away from cAMP. This challenges the current view that
all PKA orthologues are cAMP-dependent and explains why
earlier attempts to detect cAMP-stimulated kinase activity23,24 or
binding of cAMP to recombinantly expressed domain fragments
of trypanosomal PKAR orthologs22,27 remained negative. The
CNB domain seems to be a more versatile ligand-binding
domain, not limited to cyclic nucleotides, as reported for some
distant CNB family members in prokaryotes3,4. We expect that
systematic surveys will identify novel eukaryotic CNB domain
binding speciﬁcities, not only in phylogenetically distant
trypanosomatids.
Several conserved amino acids in the CNB domains of PKAR
from T. brucei and related kinetoplastids depart from the con-
sensus (see Fig. 4f, g), as noted earlier22,27,31. Yet, the amino acid
sequence alone did not allow the prediction of altered ligand
speciﬁcity. For example, the consensus arginine interacting with
the exocyclic phosphate of cAMP in almost all PKAs (R333 in
Fig. 3 Activators of trypanosome PKA. a Hit compounds with their EC50 of in vivo PKA activity (VASP reporter assay, mean ± SD, n= 3 independent
replicates, representative western blots as inset) and their EC50 of in vitro kinase activity (kemptide phosphorylation by T. brucei PKAR-PKAC1 holoenzyme
expressed in L. tarentolae). A representative dose response for Toyo (n= 5), 5-I-Tu (n= 4), 5-Br-Tu (n= 2), tubercidin (n= 2), and sangivamycin (n= 1) is
shown with SD of technical duplicates or triplicates. Binding parameters to T. brucei PKAR(199–499) expressed in E. coli were determined by isothermal
titration calorimetry (ITC). The power differential (DP) between the reference and sample cells upon injection was measured as a function of time (inset).
The main plot presents the total heat exchange per mole of injectant (integrated peak areas from inset) as a function of the molar ratio of ligand to protein.
One out of three independent replicates is shown. b Data for 7-CN-7-C-Ino as in a; for number of independent replicates see Table 1. The EC50 and KD
values given in a and b are rounded values from Table 1. c Thermodynamic signature (ΔG in blue, ΔH in green, and −TΔS in red) compiled from ITC
measurements (mean ± SD of n= 3 independent replicates) in a and b. Source data are provided as a Source Data ﬁle
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bovine RIα) is one of the key replacements in kinetoplastid
PKAR, but the mammalian RIα mutant of that residue retained
cAMP activation at an only 5-fold decreased EC5054. Our co-
crystal structure shows that glutamate residues (E312/E436)
present in both CNB pockets of TcPKAR may clash with the
negatively charged phosphate of cAMP (Supplementary Movie 5)
but strengthen the interaction with the ribose moiety of 7-CN-7-
C-Ino. In addition, an important role of the αD helix, an extra
helix only present at the C-terminus of trypanosome PKAR is
suggested. These features are conserved in the Trypanosoma
species T. brucei and T. cruzi that share the unusual ligand
binding. The high afﬁnity of the 7-deaza nucleoside analogues can
be explained by interactions with side groups on the purine ring.
For example, a hydrogen bond donor–acceptor pair (Y486/
N–K482/O) from the backbone of the trypanosome-speciﬁc αD
helix (see Fig. 4e) favours the interaction with a ligand having an
acceptor–donor pair at positions 1 and 6 of the purine ring. This
is the case for the hypoxanthine-like purine ring in 7-CN-7-C-Ino
(Fig. 4e, Supplementary Fig. 7b) but not the adenine-like purine
ring in toyocamycin. In silico docking shows that the bulky
cyano-, iodo-, or bromo- side groups ﬁll a small hydrophobic
pocket formed at the interface between the beta barrel (V444) and
the αD helix (V489, Y485, Y486) in CNB-B, and correctly pre-

























































Fig. 4 Co-crystal structure of trypanosome PKAR with 7-CN-7-C-Ino. a Structural alignment of T. cruzi PKAR(200–503) (chain representation in blue) and
Bos taurus PKARIα(92–308) (PDB 1RGS, chain representation in grey). The two capping residues and the salt bridge pair are highlighted by their carbon
atoms colour-coded as green and magenta in the B. taurus and T. cruzi PKAR structures, respectively. The overlay of ligand poses is shown in the blow-ups
and the π-stacking interactions in both sites for both proteins are highlighted. b, c Fo–Fc (3σ, green) and 2Fo–Fc (1σ, blue) maps of TcPKAR CNB-A and
CNB-B, respectively, showing 7-CN-7-C-Ino modelled to ﬁt the electron densities. d, e Hydrogen bonding network (black dashed lines) of 7-CN-7-C-Ino
bound to TcPKAR(200–503) CNB-A and CNB-B, respectively. The capping residues in CNB-A (Y371) and CNB-B (Y483) are labelled in magenta. 3D
versions of a, d, and e are available as Supplementary Movie 1, 3, and 4, respectively. f, g Sequence alignment of PKAR in CNB-A and CNB-B, respectively,
of representative kinetoplastid parasites with a mammalian PKAR (B. taurus PKARIα) as reference. Numbering refers to T. cruzi (top) and B. taurus
(bottom), respectively
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Fig. 7c). The low potency of sangivamycin can also be explained
by the incompatibility of its bulky and hydrophilic side group
with the small hydrophobic pocket. Interestingly, the second
highest afﬁnity to the B-site is predicted for tubercidin, while the
kinase activation potency of this ligand is second lowest. Tuber-
cidin has no side group at position 7; its ribose ring can sample
more conformations and therefore possibly score higher in
docking. The missing contact to the αD helix is however corre-
lated with low potency. This suggests a role of this trypanosome-
speciﬁc helix not only for binding but also for the conformational
change that underlays the activation mechanism. Only recently,
the critical residues for cyclic nucleotide selectivity (cAMP/
cGMP) between PKA and PKG have been deﬁned52,55. Mutations
G316R/A336T in CNB-B convert hRIα from low to high cGMP
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Fig. 5 Target phosphorylation and expression changes. a Global display of proteins phosphorylated at RXXS/T sites. Wild type (WT) or Δpkar/Δpkar (pkar KO)
cells were treated or not (−) with 2 µMToyo or 7-CN-7-C-Ino (Ino) for 10min and lysates were subjected to western blotting with anti-phospho-RXXS*/T* and
anti-PFR-A/C as loading control. M: protein molecular weight marker. b Volcano plot representation of phosphopeptides quantiﬁed by label-free
phosphoproteome analysis. Phosphopeptides are plotted according to p-value and fold change caused by treatment of T. bruceiWT cells with 7-CN-7-C-Ino (8
µM, 15min, n= 4 independent experiments) in comparison to untreated cells (n= 4 independent experiments). Phosphopeptides that change signiﬁcantly in
abundance (FDR≤0.05, s0= 2) and contain phosphosites matching PKA consensus motifs (R/K-X-X-S/T, R/K-X-S/T)5 are shown as red dots; signiﬁcantly
changed phosphopeptides without PKA consensus motifs are shown in black. c Pie charts showing the fraction of PKA consensus motifs (red) within the
downregulated (n= 84, left) or upregulated (n= 642, right) phosphosites. The frequency of individual subsets of PKA motifs (upregulated) was compared to
the human PKA site motif frequency retrieved from the PhosphoSitePlus database (https://www.phosphosite.org). d Abundance changes of metacaspase
4 (MCA4) and PKAC1/2 in WT or e pkar KO cells after treatment with 4 µM 7-CN-7-C-Ino (Ino) or Toyo in a 24-h time course. Western blot signals were
normalized to the loading control PFR-A/C; untreated WT cells were set to 1. Source data to a and c–e are provided as a Source Data ﬁle
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afﬁnity. Of note, the residue corresponding to A336 in hRIα is
V444 in TcPKAR and is part of the hydrophobic pocket formed
between beta barrel and αD helix. This pocket accommodates the
substituent at the C7 position of our activators and may deter-
mine their selectivity.
The structural alignment between TcPKAR and bovine
PKARIα shows conservation of the general polypeptide chain
folding and of the putative salt bridge and capping residues linked
to the extensively studied allosteric activation mechanism in
mammalian PKARIα1,30. The rapid decrease of PKAC1 levels
upon treatment of cells with 7-CN-7-C-Ino (Fig. 5d, Supple-
mentary Fig. 9a) indicates that kinase activation involves
holoenzyme dissociation in vivo. The paradigmatic features of the
signalling protein PKA seem to be conserved and adapted to
different activating ligands by minor substitutions in the PBC in
concert with the trypanosome-speciﬁc αD helix extension in
CNB-B. It follows that some of the “orphan” CNB domains
identiﬁed in eukaryotic genomes2,31,56,57 may be regulated by
unexpected and novel ligands. Such discoveries will be as
insightful as was the discovery of ligands for other classes of
orphan receptors, e.g. from the G-protein coupled receptor58 or
nuclear hormone receptor59 families.
Our report on this unique cAMP-independent PKA may
appear to question the role of cAMP as second messenger in
trypanosomes. Homologs of other known effector proteins like
Epac or cyclic nucleotide gated ion channels were not found in
the T. brucei genome. Yet, cAMP and the enzymes for its pro-
duction and degradation are present and play vital roles in cell
division and host immunity subversion12,17–20. We have pre-
viously identiﬁed a number of potential cAMP response proteins
(CARPs) by genome-wide RNAi library screening in T. brucei29.
CARP1 has three CNB domains and the T. cruzi ortholog60 binds
cAMP. Interestingly, CARP1 is exclusively found in kinetoplastid
genomes and possibly coevolved with the ligand swap of PKA
away from cAMP. There are also additional candidate genes with
predicted CNB domains, some of which may be cAMP
effectors41,60. Divergent CNB domains as found in cAMP-
binding Popeye-domain proteins61 might be present but not
recognized due to limited homology. Together, the cAMP-
independence of PKA in trypanosomes is well compatible with
cAMP signalling in these organisms.
7-CN-7-C-Ino is a potent activator and has low toxicity in vivo,
in contrast to the 7-deazaadenosine analogues. The latter com-
pounds are known to have pleiotropic effects in various cell types
by interfering with cellular processes involving nucleosides or
nucleotides. This comprises inhibition of kinases and inhibition
of DNA, RNA, and protein synthesis (reviewed in ref. 47) and
explains the broad antibiotic and antineoplastic activity proﬁle. A
possible reason for the reduced off-target effects of 7-CN-7-C-Ino
might be lower in vivo stability of the drug. This should not affect
the short term in vivo kinase reporter assay but reduce off-target
effects on growth and viability. In trypanosomes, toxicity of the 7-
deazaadenosine analogues is clearly not mediated by PKA, as we
ﬁnd no difference between WT and Δpkar/Δpkar cells. A base
level of catalytic PKA function is essential for growth and viability
of T. brucei (Supplementary Fig. 2). Therefore, efﬁcient inhibition
of PKA activation by trapping the catalytic subunits in inactive
holoenzyme complexes would reduce the free kinase to lethal
level. The challenge in view of possible antiparasitic drug devel-
opment will be to turn our novel activators to PKA inhibitors
similar to what had been achieved for mammalian PKA62. As this
work shows, TbPKA is essential, druggable, and has a ligand
speciﬁcity differing from PKAR of the mammalian host. Due to
conservation of the substitutions in the CNBs in different kine-
toplastid PKAs, such inhibitors may also target the orthologues of
related kinetoplastid pathogens like Leishmania.
With 7-CN-7-C-Ino, we contribute a potent chemical tool that
will spur further investigations on the cellular PKA targets and
physiological functions in trypanosomes. Our 7-CN-7-C-Ino-
induced phosphoproteome returned a surprising number of
highly upregulated P-sites, mostly (77%) within PKA consensus
motifs. The GO terms most enriched among the target proteins
are related to posttranscriptional control of gene expression and
signalling. PKA phosphorylates directly or indirectly 17 other
kinases, indicating interconnection with other signalling path-
ways. Participation in posttranscriptional control is not surprising
as many RNA binding proteins and regulators of RNA stability or
translation are regulated by phosphorylation in many organ-
isms63. In trypanosomes, gene expression is almost exclusively
controlled at the posttranscriptional level64. Therefore, PKA that
participates in transcriptional regulation in other eukaryotes, may
be redirected to the targets that exert gene expression control in
trypanosomes. The cytokinesis phenotypes observed upon genetic
perturbation of TbPKA (Supplementary Fig. 2 and ref. 35) cor-
respond well to enriched GO terms related to cell division and
cytokinesis. The enrichment for cytoskeletal structures and the
ﬂagellum perfectly correspond to the subcellular localization of
PKAR in the ﬂagellum65, a motility phenotype65 and cytokinesis,
a process that depends on the ﬂagellum66. Surprisingly, the
quantitative proteome analysis upon induction with 7-CN-7-C-
Ino returned only 14 proteins signiﬁcantly regulated in abun-
dance after 12 h. Among them, downregulation of MCA4, an
unconventional metacaspase regarded as pseudopeptidase53 is
interesting, since T. brucei mutants with homozygous deletion of
MCA4 have reduced virulence in animal infections53.
The in vivo pathways and mechanisms upstream of PKA in
trypanosomes are completely elusive to date. Is trypanosome
PKA the effector of an unknown alternative second messenger?
The direct activators of T. brucei PKA identiﬁed by this work
include tubercidin, toyocamycin, and sangivamycin, natural
antibiotics that are secondary metabolites of Streptomyces
strains67. However, it seems unlikely that 7-deazapurines are the
endogenous PKA ligands, since no homologs of the Streptomyces
genes encoding enzymes required for synthesis of the precursor
preQ068 were detected in the T. brucei genome. Of course, an
alternative route of synthesis of a 7-deazapurine cannot be
excluded. As we ﬁnd indirect activation of T. brucei PKA by
dipyridamole in live cells, this antimetabolite may perturb the
parasite’s nucleoside metabolism, e.g. by blocking uptake of
adenosine69. Nucleoside-related metabolites or by-products of
purine salvage may have adopted the role of second messenger-
like molecules targeting PKA in trypanosomes. The identity of the
physiological PKA ligand and the respective pathway is an
exciting line of current research.
Methods
Trypanosome culture conditions. Bloodstream forms of the monomorphic Try-
panosoma brucei brucei strain Lister 427, variant MiTat 1.270, were cultivated at 37
°C and 5% CO2 in modiﬁed HMI-9 medium14 supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS). Cell lines 13–9071 or 1313–51472 expressing
T7 polymerase and Tet repressor were kept under continuous selection with 2.5 µg
ml−1 G418 and 5 µg ml−1 hygromycin B or 0.2 µg ml−1 phleomycin and 2 µg ml−1
G418, respectively.
Immunopuriﬁcations. PTP puriﬁcation was performed according to the protocol of
Schimanski et al.73 with a few modiﬁcations. Brieﬂy, trypanosomes expressing PTP-
tagged PKAR from the endogenous locus were lysed in PA-150 buffer (w/o DTT,
supplemented with Complete Mini EDTA-free protease inhibitor cocktail (Roche)
and 25 µgml−1 pepstatin A) by three sonication cycles 30 s each with the Bioruptor
device (Diagenode) at low power. After centrifugation (20min, 20,000 × g, 4 °C), the
cleared supernatant was incubated with IgG beads (pre-equilibrated with PA-150
buffer) for 4 h to overnight by overhead rotation at low speed. Two washes with PA-
150 buffer and one with PBS were followed by elution of proteins bound to the IgG
beads by incubation with 2× Laemmli sample buffer (125mM Tris, pH 6.8, 4% (w/v)
SDS, 20% (v/v) glycerol, 10% 2-mercaptoethanol, 0.02% (w/v) bromophenol blue) for
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5min at 95 °C. Immunoprecipitation of Ty1- or HA-tagged PKA subunits was per-
formed by incubation of trypanosomes in lysis buffer (50mM Tris, pH 7.2, 2 mM
EGTA, 150mM NaCl, 0.2% NP-40, 1mM NaVO4, 0.5% aprotinin, 2 µgml−1 leu-
peptin, 1mM PMSF) for 10min on ice with subsequent clearing of the supernatant by
centrifugation (20min, 20,000 × g, 4 °C). The cleared lysate was incubated with the
respective epitope-tag antibody coupled covalently (using the cross-linker DMP
(Thermo Scientiﬁc) according to the manufacturer’s instructions) or non-covalently
to protein G sepharose beads (Amersham Pharmacia) for 1 h to overnight.
In vivo PKA reporter assay. Trypanosomes were harvested (10 min, 1400 × g,
37 °C) and resuspended in HMI-9 medium (pre-heated to 37 °C) to a density of
5 × 107 cells ml−1. After a 5–10 min recovery at 37 °C with mild shaking, test
compounds or solvent were added to the cell suspension followed by careful
mixing. After incubation at 37 °C for the speciﬁed time period, cells were lysed with
6× Laemmli sample buffer preheated to 95 °C and incubated for 5 min at 95 °C.
Incubation of trypanosomes at this density for up to 30 min had no effect on VASP
phosphorylation (Supplementary Fig. 3g). GraphPad Prism 7.0 was used for EC50
calculation by non-linear regression analysis using an equation for a sigmoidal
dose–response curve with variable slope. The same software was used for visuali-
zation of all graphs and bar charts.
Inhibitors and nucleoside analogues. PKI(5–24) and myr-PKI(14–22) were
obtained from Biomol. CpdA19 (now renamed as NPD-001)74 was synthesized by
Geert-Jan Sterk, Mercachem. Dipyridamole was obtained from Sigma-Aldrich,
toyocamycin and sangivamycin from Berry & Associates. All other nucleoside and
cyclic nucleotide analogues were obtained from Biolog GmbH, Bremen. 7-CN-7-C-
Ino was synthesized according to Hinshaw et al.75 with 125 mg (429.1 µmol) Toyo
as starting material. By variation to the original protocol, the raw product was
puriﬁed by reversed phase medium pressure liquid chromatography (MPLC).
Brieﬂy, the raw product was dissolved in 20 ml water, ﬁltrated and applied to a
Merck LiChroprep® RP-18 column (15–25 µM; 125 × 35 mm), previously equili-
brated with water. The column was washed with water to remove excess of inor-
ganic salts and hydrophilic impurities. Afterwards, 1% and 2% 2-propanol in water
was used to elute the target compound. Product-containing fractions were con-
centrated by rotary evaporation under reduced pressure and subsequently freeze-
dried to yield 89.34 mg (305.7 µmol) of 7-CN-7-C-Ino with a purity of 99.93% by
analytical HPLC (ODS-A 120-11, RP-18 (YMC, Dinslaken, Germany); 250 × 4
mm; 9% acetonitrile, 20 mM triethylammonium buffer, pH 6.8; 1.0 ml min−1; UV-
detection at 265 nm).
Leishmania tarentolae expression system. The L. tarentolae strain LEXSY T7-TR
(Jena Biosciences) was cultivated at 26.5 °C in BHI medium supplemented with 10
µg ml–1 hemin, 100 U L−1 streptomycin and 100 mg L−1 penicillin according to the
protocols provided by Jena Biosciences. For maintenance of T7 polymerase and Tet
repressor, 10 µg ml−1 nourseothricin (NTC) and 10 µg ml−1 hygromycin B were
added to the medium. For co-expression of T. brucei PKAR-10 × His and Strep-
PKAC1, the full length ORFs were ampliﬁed from genomic DNA using primers
introducing the respective epitope tag and cloned into pLEXSY_I-ble3 and
pLEXSY_I-neo3 (Jena Biosciences), respectively. Details on primer sequences and
cloning strategies are available upon request. Cells transfected with both constructs
were cultivated in the presence of 100 µg ml−1 phleomycin and 50 µgml−1 G418.
L. tarentolae cells at mid log phase (2–3 × 107 cells ml−1) were induced with 10 µg
ml−1 tetracycline for 24 h. Lysis of cells in 50 mM Tris, pH 7.4, 150 mM NaCl, 0.2%
Triton X-100, 1 mM 2-mercaptoethanol was completed by a Dounce homogenizer.
Tandem afﬁnity puriﬁcation of the holoenzyme complex was performed to guar-
antee subunit stoichiometry and highest purity: His-tag puriﬁcation using Ni-NTA
beads (Thermo Fisher Scientiﬁc) was followed by Strep-tag puriﬁcation using
gravity ﬂow chromatography and StrepTactin sepharose beads (IBA), according to
the manufacturers’ instructions. The eluted fractions were pooled and dialyzed
against the kinase storage buffer (20 mM MOPS, pH 7.0, 150 mM NaCl, 1 mM
2-mercaptoethanol).
In vitro kinase assay. A radioactive PKA kinase assay was performed according to
Hastie et al.76, using 100 µM Kemptide (LRRASLG) as kinase substrate and 100 µM
ATP spiked with [γ-32P] ATP to give 200–400 cpm pmol−1. GraphPad Prism 7.0
was used for EC50 calculation by non-linear regression analysis using an equation
for a sigmoidal dose–response curve with variable slope. The same software was
used for visualization of all graphs and bar charts.
Binding studies by isothermal titration calorimetry. N-terminally truncated T.
brucei PKAR (aa 199–499) was cloned into pETDuet-1 (Novagene) with an N-
terminal His6-tag and expressed in E. coli Rosetta (DE3). The bacteria were grown
in Luria–Bertani (LB) medium to OD600 of ∼0.4 at 37 °C, followed by overnight
induction with 0.4 mM IPTG at 20 °C. Cells were harvested by centrifugation and
lysed in a French Press. Protein puriﬁcation was done by Ni-NTA afﬁnity chro-
matography, followed by elution in 50 mM HEPES, pH 7.5, 50 mM NaCl, and 250
mM imidazole. Eluted protein (∼7 mgml−1) was dialyzed overnight in 50 mM
HEPES, pH 7.5, 50 mM NaCl, 1 mM DTT, and stored at −80 °C. Ligand-free
protein for binding studies was prepared by adding solid urea to the protein
solution to a ﬁnal concentration of 8 M. After 1 h at 25 °C, the solution was passed
over a prepacked PD10 column (GE Healthcare) equilibrated with 8 M urea, 50
mM HEPES, pH 8.5, 50 mM NaCl. TbPKAR(199–499) was refolded overnight by
dialysis against 50 mM Tris, pH 8.5, 240 mM NaCl, 10 mM KCl, 2 mM MgCl2, 2
mM CaCl2, 0.4 M sucrose, 1 mM DTT at 4 °C, followed by separation of monomers
from aggregates by size-exclusion chromatography on a Superdex 200 Increase 10/
300 GL column (GE Healthcare) equilibrated with 50 mM HEPES, pH 7.5, 50 mM
NaCl, and 1% DMSO (buffer A). Eluted protein was diluted to 10 µM for ITC. The
human PKARIα (full size) was expressed from the pETDuet-1 based plasmid 6H.
tev/HsPKARα in E. coli Rosetta D3, prepared cAMP-free according to Buechler
et al.77 with the following modiﬁcation: the refolding buffer was the buffer used for
TbPKAR refolding. The puriﬁed protein was diluted to 5 µM. For binding assays,
13–19 injections of 2–3 µl were performed with a MicroCal PEAQ-ITC (Malvern)
instrument. In each series, 100 µM of ligand (prepared using buffer A) was injected
at 298 K into 5–10 µM protein freshly eluted from size exclusion chromatography.
Binding constants and thermodynamic data were derived from best least square ﬁt
analysis, applying a model with two binding sites (performed with MicroCal
PEAQ-ITC software).
Quantitative phosphoproteomics. For each sample, 6 × 108 T. brucei cells treated
or not with 8 µM 7-cyano-7-deazainosine for 15 min were lysed in 300 µl 4% (w/v)
sodium deoxycholate, 0.1 M Tris, pH 8.5 for 5 min at 95 °C (according to the
protocol of Humphrey et al.78). Samples were sonicated using a Bioruptor (Diag-
enode) (high power, two cycles of 10 min each, 30 s on/off). Protein concentration
was determined by BCA protein assay and samples were adjusted to equal con-
centrations. Sample preparation and mass spectrometry were exactly carried out as
described by Humphrey et al.78. MaxQuant 1.5.2.879 was used to identify proteins
and quantify by LFQ with the following parameters: Database, TriTrypDB-
39_TbruceiTREU927_AnnotatedProteins; MS tol, 10 ppm; MS/MS tol, 0.5 Da;
Peptide FDR, 0.1; Protein FDR, 0.01 Min. peptide Length, 5; Variable modiﬁca-
tions, Oxidation (M), Phosphorylation (STY); Fixed modiﬁcations, Carbamido-
methyl (C); Peptides for protein quantitation, razor and unique; Min. peptides, 1;
Min. ratio count, 2. For proteomic analysis, identiﬁed proteins were considered as
statistically signiﬁcant with FDR ≤ 0.05 and s0= 1 (two-sided Student’s T-test
adjusted for multiple comparisons by Benjamini–Hochberg correction, Perseus80).
Phosphopeptide analysis was carried out in Perseus as suggested by Humphrey
et al.78. The mass spectrometry phosphoproteomics data have been deposited to
the ProteomeExchange Consortium via the PRIDE partner repository (https://
www.ebi.ac.uk/pride/archive) with the dataset identiﬁer PXD012245. GO enrich-
ment analysis was performed in TriTrypDB with default settings and visualized in
Revigo (http://revigo.irb.hr). The motif discovery tool MoMo (using the motif-x
algorithm) implemented in the MEME suite (http://meme-suite.org/) was used for
unbiased motif discovery in the phosphoproteome dataset with the T. brucei
TriTrypDB-40_TbruceiTREU927 protein database as background. Enriched
sequence logos were visualized using CLC Main Workbench 7 (https://www.
qiagenbioinformatics.com/).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The coordinates of the T. cruzi PKAR crystal structure bound to 7-CN-7-C-Ino have
been deposited in the Protein Data Bank under the code PDB 6FTF. The
phosphoproteome and proteome datasets are available in the PRIDE partner repository
with the dataset identiﬁers PXD012245 and PXD009073, respectively. Genome sequence
and annotation information was obtained from TritrypDB (http://www.tritrypdb.org).
Human PKA substrates and phosphorylation motifs were retrieved from the
PhosphoSitePlus database (https://www.phosphosite.org). Gene ontology (GO)
enrichment analysis was visualized using Revigo (http://revigo.irb.hr). The motif
discovery tool MoMo implemented in the MEME suite (http://meme-suite.org) was used
for unbiased motif discovery in the phosphoproteome dataset. The source data
underlying Figs. 1c, d, 2a–h, 3a–c, 5a, c–e, Table 1, and Supplementary Figs. 1b, 2, 3a–d,
f–i, 4a–h, 8a–c, 9a–c are provided as Source Data ﬁle.
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